ApoC-III interacts also with apoE in modulating HDL metabolism and CAD risk [48], and four large prospective cohort studies have supported the idea that HDL-rich in ApoC-III correlate with increased CHD risk [49]. This evidence concerns the gene APOC3 and coronary artery disorder.